• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗蠕虫药尼氯硝唑破坏 p65 和 FOXM1/β-连环蛋白的相互作用并根除慢性髓性白血病中的白血病干细胞。

Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia.

机构信息

State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.

Department of Pathophysiology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.

出版信息

Clin Cancer Res. 2017 Feb 1;23(3):789-803. doi: 10.1158/1078-0432.CCR-16-0226. Epub 2016 Aug 4.

DOI:10.1158/1078-0432.CCR-16-0226
PMID:27492973
Abstract

PURPOSE

Leukemia stem cells (LSC), which are insensitive to tyrosine kinase inhibitors (TKI), are an important source of TKI resistance and disease relapse in chronic myelogenous leukemia (CML). Obstacles to eradicating LSCs include limited understanding of the regulation network of LSCs. The current study aimed to examine the interplay between NF-κB and FOXM1/β-catenin, and the effect of its chemical intervention on CML LSCs.

EXPERIMENTAL DESIGN

The interplay between NF-κB and FOXM1/β-catenin was analyzed by reciprocal coimmunoprecipitation (co-IP) and chromatin immunoprecipitation (ChIP) assay in CML cells. The effect of disturbing NF-κB and FOXM1/β-catenin by niclosamide on the self-renewal capacity and survival of LSCs was evaluated in vitro in human primary CML CD34 cells and in vivo in CML mice.

RESULTS

Reciprocal co-IP experiments showed physical interaction of p65 and FOXM1. p65 promoted transcription of FOXM1 gene. ChIP assay revealed recruitment of p65 on the promoter of FOXM1 gene. Conversely, FOXM1 and β-catenin positively regulated the nuclear translocation and transcriptional activity of NF-κB in CML cells. Niclosamide disrupted the positive feedback loop between NF-κB and FOXM1/β-catenin, thereby impairing the self-renewal capacity and survival of CML LSCs. Niclosamide decreased the long-term engraftment of human CML LSCs in NOD-SCID IL2Rγ chain-deficient (NOG) mice, and prolonged the survival of CML mice.

CONCLUSIONS

Interaction of p65 with FOXM1/β-catenin is critical in CML and its disruption by niclosamide eradicates LSCs. These findings may improve the understanding of a self-renewal regulatory mechanism of LSCs and offer a rationale-based approach to eliminate LSCs in CML. Clin Cancer Res; 23(3); 789-803. ©2016 AACR.

摘要

目的

白血病干细胞(LSC)对酪氨酸激酶抑制剂(TKI)不敏感,是慢性髓性白血病(CML)中 TKI 耐药和疾病复发的重要来源。根除 LSC 的障碍包括对 LSC 调节网络的认识有限。本研究旨在研究 NF-κB 和 FOXM1/β-catenin 之间的相互作用,以及其化学干预对 CML LSC 的影响。

实验设计

通过 CML 细胞中的相互共免疫沉淀(co-IP)和染色质免疫沉淀(ChIP)实验分析 NF-κB 和 FOXM1/β-catenin 之间的相互作用。在人原代 CML CD34 细胞中和 CML 小鼠体内,通过尼克罗米德干扰 NF-κB 和 FOXM1/β-catenin 对 LSC 自我更新能力和存活的影响进行体外评估。

结果

相互 co-IP 实验表明 p65 和 FOXM1 之间存在物理相互作用。p65 促进 FOXM1 基因的转录。ChIP 实验显示 p65 募集到 FOXM1 基因的启动子上。相反,FOXM1 和 β-catenin 正向调节 CML 细胞中 NF-κB 的核转位和转录活性。尼克罗米德破坏了 NF-κB 和 FOXM1/β-catenin 之间的正反馈回路,从而损害了 CML LSC 的自我更新能力和存活。尼克罗米德减少了人 CML LSC 在 NOD-SCID IL2Rγ 链缺陷(NOG)小鼠中的长期植入,并延长了 CML 小鼠的存活时间。

结论

p65 与 FOXM1/β-catenin 的相互作用在 CML 中是至关重要的,尼克罗米德的破坏可根除 LSC。这些发现可能提高对 LSC 自我更新调节机制的认识,并为消除 CML 中的 LSC 提供基于理论的方法。临床癌症研究;23(3);789-803。©2016AACR。

相似文献

1
Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia.抗蠕虫药尼氯硝唑破坏 p65 和 FOXM1/β-连环蛋白的相互作用并根除慢性髓性白血病中的白血病干细胞。
Clin Cancer Res. 2017 Feb 1;23(3):789-803. doi: 10.1158/1078-0432.CCR-16-0226. Epub 2016 Aug 4.
2
Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.靶向甲基转移酶PRMT5可消除慢性粒细胞白血病中的白血病干细胞。
J Clin Invest. 2016 Oct 3;126(10):3961-3980. doi: 10.1172/JCI85239. Epub 2016 Sep 19.
3
Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.通过 N-钙黏蛋白和 Wnt-β-连环蛋白信号转导对慢性髓性白血病干细胞和祖细胞进行微环境保护,免受酪氨酸激酶抑制剂的影响。
Blood. 2013 Mar 7;121(10):1824-38. doi: 10.1182/blood-2012-02-412890. Epub 2013 Jan 8.
4
Depletion of γ-catenin by Histone Deacetylase Inhibition Confers Elimination of CML Stem Cells in Combination with Imatinib.通过组蛋白去乙酰化酶抑制作用消耗γ-连环蛋白可与伊马替尼联合消除慢性粒细胞白血病干细胞。
Theranostics. 2016 Aug 12;6(11):1947-62. doi: 10.7150/thno.16139. eCollection 2016.
5
Gas6/AXL Signaling Regulates Self-Renewal of Chronic Myelogenous Leukemia Stem Cells by Stabilizing β-Catenin.Gas6/AXL 信号通过稳定β-连环蛋白调节慢性髓性白血病干细胞的自我更新。
Clin Cancer Res. 2017 Jun 1;23(11):2842-2855. doi: 10.1158/1078-0432.CCR-16-1298. Epub 2016 Nov 16.
6
Anthelmintic drug niclosamide enhances the sensitivity of chronic myeloid leukemia cells to dasatinib through inhibiting Erk/Mnk1/eIF4E pathway.抗蠕虫药氯硝柳胺通过抑制Erk/Mnk1/eIF4E通路增强慢性髓性白血病细胞对达沙替尼的敏感性。
Biochem Biophys Res Commun. 2016 Sep 16;478(2):893-9. doi: 10.1016/j.bbrc.2016.08.047. Epub 2016 Aug 9.
7
Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant.驱虫药尼氯硝唑通过使 Sp1 失活来抑制 BCR-ABL 融合癌基因的转录,并诱导携带 T315I 突变的耐伊马替尼 CML 细胞凋亡。
Cell Death Dis. 2018 Jan 22;9(2):68. doi: 10.1038/s41419-017-0075-7.
8
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors.极光激酶 A- polo 样激酶 1-FOXM1 轴的过度激活促进慢性髓性白血病对酪氨酸激酶抑制剂的耐药性。
J Exp Clin Cancer Res. 2019 May 23;38(1):216. doi: 10.1186/s13046-019-1197-9.
9
Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.β-连环蛋白和Bcr-Abl的联合抑制在体外和体内协同靶向酪氨酸激酶抑制剂耐药的急变期慢性髓性白血病母细胞和祖细胞。
Leukemia. 2017 Oct;31(10):2065-2074. doi: 10.1038/leu.2017.87. Epub 2017 Mar 21.
10
Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.miR-29a-3p、miR-494-3p和miR-660-5p的表达失调会影响慢性粒细胞白血病白血病干细胞对酪氨酸激酶抑制剂的敏感性。
Oncotarget. 2017 Jul 25;8(30):49451-49469. doi: 10.18632/oncotarget.17706.

引用本文的文献

1
GLP and G9a histone methyltransferases as potential therapeutic targets for lymphoid neoplasms.GLP和G9a组蛋白甲基转移酶作为淋巴样肿瘤的潜在治疗靶点。
Cancer Cell Int. 2024 Jul 12;24(1):243. doi: 10.1186/s12935-024-03441-y.
2
Exploiting the potential of the ubiquitin-proteasome system in overcoming tyrosine kinase inhibitor resistance in chronic myeloid leukemia.利用泛素-蛋白酶体系统在克服慢性髓性白血病中酪氨酸激酶抑制剂耐药性方面的潜力。
Genes Dis. 2023 Oct 26;11(5):101150. doi: 10.1016/j.gendis.2023.101150. eCollection 2024 Sep.
3
Niclosamide combined to Azacitidine to target TP53-mutated MDS/AML cells.
硝唑尼特与阿扎胞苷联合用于靶向TP53突变的骨髓增生异常综合征/急性髓系白血病细胞。
Leukemia. 2024 Jul;38(7):1630-1633. doi: 10.1038/s41375-024-02281-z. Epub 2024 May 22.
4
High G9a Expression in DLBCL and Its Inhibition by Niclosamide to Induce Autophagy as a Therapeutic Approach.弥漫性大B细胞淋巴瘤中G9a高表达及其被氯硝柳胺抑制以诱导自噬作为一种治疗方法
Cancers (Basel). 2023 Aug 17;15(16):4150. doi: 10.3390/cancers15164150.
5
targeting miR-181a mimic and saRNA overcome imatinib resistance in BCR-ABL1-independent chronic myeloid leukemia by suppressing leukemia stem cell regeneration.靶向miR-181a模拟物和saRNA通过抑制白血病干细胞再生克服非BCR-ABL1依赖型慢性髓性白血病中的伊马替尼耐药性。
Mol Ther Nucleic Acids. 2023 May 4;32:729-742. doi: 10.1016/j.omtn.2023.04.026. eCollection 2023 Jun 13.
6
TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia.骨髓增生异常综合征和急性髓系白血病中的TP53改变
Biomedicines. 2023 Apr 11;11(4):1152. doi: 10.3390/biomedicines11041152.
7
Niclosamide is a potential candidate for the treatment of chemo-resistant osteosarcoma.氯硝柳胺是治疗化疗耐药性骨肉瘤的潜在候选药物。
Genet Mol Biol. 2023 Feb 3;46(1):e20220136. doi: 10.1590/1678-4685-GMB-2022-0136. eCollection 2023.
8
Comprehensive analysis of family expression and prognosis in acute myeloid leukemia.急性髓系白血病家族表达与预后的综合分析
Front Genet. 2023 Jan 9;13:1087938. doi: 10.3389/fgene.2022.1087938. eCollection 2022.
9
Developing therapeutic approaches for chronic myeloid leukemia: a review.开发治疗慢性髓细胞白血病的方法:综述。
Mol Cell Biochem. 2023 May;478(5):1013-1029. doi: 10.1007/s11010-022-04576-0. Epub 2022 Oct 10.
10
MELK predicts poor prognosis and promotes metastasis in esophageal squamous cell carcinoma via activating the NF‑κB pathway.MELK 通过激活 NF-κB 通路预测食管鳞癌不良预后并促进转移。
Int J Oncol. 2022 Aug;61(2). doi: 10.3892/ijo.2022.5384. Epub 2022 Jun 22.